Effect of Additional Trastuzumab in Neoadjuvant and Adjuvant Treatment for Patients with Resectable HER2-Positive Gastric Cancer

被引：0
|
作者：
Qifei He
Jiahui Chen
Kai Zhou
Chenggen Jin
Anqiang Wang
Ke Ji
Xin Ji
Ji Zhang
Xiaojiang Wu
Xia Li
Zhaode Bu
Jiafu Ji
机构：
[1] Peking University Cancer Hospital and Institute,Department of Gastrointestinal Surgery, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)
[2] Karolinska Institutet,Department of Medical Epidemiology and Biostatistics
来源：
Annals of Surgical Oncology | 2021年 / 28卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4413 / 4422
页数：9
相关论文
共 50 条
  • [21] An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia
    Antonio Buendia, Jefferson
    Vallejos, Carlos
    Pichon-Riviere, Andres
    BIOMEDICA, 2013, 33 (03): : 411 - 417
  • [22] Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer
    Li, Zhifei
    Zhao, Huan
    Hu, Huihui
    Shang, Haili
    Ren, Yongjing
    Qiu, Wenhui
    Su, Hao
    Lyu, Huifang
    Chen, Xiaobing
    CHINESE JOURNAL OF CANCER RESEARCH, 2024, 36 (03)
  • [23] Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
    Chang, Helena R.
    CANCER, 2010, 116 (12) : 2856 - 2867
  • [24] The Effect of Adding Pertuzumab to Adjuvant Trastuzumab in Early HER2-Positive Breast Cancer
    Al-Azawi, Ahmed
    Hneua, Riyadh Abd-Alrasool
    Hameed, Rana Majeed
    Hassan, Duha Maithem
    JOURNAL OF CONTEMPORARY MEDICAL SCIENCES, 2023, 9 (03): : 197 - 200
  • [25] Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
    Advani, Pooja
    Cornell, Lauren
    Chumsri, Saranya
    Moreno-Aspitia, Alvaro
    BREAST CANCER-TARGETS AND THERAPY, 2015, 7 : 321 - 335
  • [26] Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients
    Mustacchi, G.
    Puglisi, F.
    Molino, A. M.
    Crivellari, D.
    Ghiotto, C.
    Ferro, A.
    Brunello, A.
    Saracchini, S.
    Turazza, M.
    Cretella, E.
    Iop, A.
    Malagoli, M.
    Stefani, M.
    FUTURE ONCOLOGY, 2015, 11 (10) : 1493 - 1500
  • [27] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Piccart-Gebhart, MJ
    Procter, M
    Leyland-Jones, B
    Goldhirsch, A
    Untch, M
    Smith, I
    Gianni, L
    Baselga, J
    Bell, R
    Jackisch, C
    Cameron, D
    Dowsett, M
    Barrios, CH
    Steger, G
    Huang, CS
    Andersson, M
    Inbar, M
    Lichinitser, M
    Láng, I
    Nitz, U
    Iwata, H
    Thomssen, C
    Lohrisch, C
    Suter, TM
    Ruschoff, J
    Süto, T
    Greatorex, V
    Ward, C
    Straehle, C
    McFadden, E
    Dolci, MS
    Gelber, RD
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1659 - 1672
  • [28] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
  • [29] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    ONCOLOGIE, 2018, 20 (01) : 43 - 44
  • [30] Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
    Mariani, Gabriella
    Fasolo, Angelica
    De Benedictis, Elena
    Gianni, Luca
    NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (02): : 93 - 104
12345